Keyword: Decibel Therapeutics
Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.
Decibel Therapeutics taps 46 Clinical to provide randomization and trial supply management.
Chimerix’s CEO replaced by a trio of officers; Decibel hires new CMO; and Kiadis poaches Ablynx’s CSO.
Decibel Therapeutics brought on a new CMO as it plans proof-of-concept and efficacy studies this year for treating hearing loss side effects.
Decibel just transformed itself into a clinical-stage biotech by licensing a phase 1 candidate from Seattle startup Oricula Therapeutics.
Decibel Therapeutics raised $55 million in a series C round and named Vir Biotechnology CEO George Scangos as chair of its board of directors.
Decibel forged an alliance with Regeneron that lets it access the big biotech’s scientific expertise without losing rights to its drug candidates.
News that the Trump administration is axing the Obama-era Deferred Action for Childhood Arrivals program has been met with dismay by biotech leaders.
Third Rock Ventures' Decibel Therapeutics has picked Boston biotech backwater the Fenway as the location for its new headquarters and laboratories.
Flagship Ventures welcomed Michael Rosenblatt, former Merck EVP and CMO, as its new CMO. Plus more hirings, firings and retirings throughout the industry.